Quantum Machine Learning Framework for Virtual Screening in Drug Discovery: a Prospective Quantum Advantage

Abstract

Machine Learning (ML) for Ligand Based Virtual Screening (LB-VS) is an important in-silico tool for discovering new drugs in a faster and cost-effective manner, especially for emerging diseases such as COVID-19. In this paper, we propose a general-purpose framework combining a classical Support Vector Classifier (SVC) algorithm with quantum kernel estimation for LB-VS on real-world databases, and we argue in favor of its prospective quantum advantage. Indeed, we heuristically prove that our quantum integrated workflow can, at least in some relevant instances, provide a tangible advantage compared to state-of-art classical algorithms operating on the same datasets, showing strong dependence on target and features selection method. Finally, we test our algorithm on IBM Quantum processors using ADRB2 and COVID-19 datasets, showing that hardware simulations provide results in line with the predicted performances and can surpass classical equivalents.

A Preprocessing Perspective for Quantum Machine Learning Classification Advantage in Finance Using NISQ Algorithms

“…PCA is one of the predominant structures for dimensionality reduction in the exploration of classic data into QML algorithms [ 16 ]. This technique is used to reduce the features and compress them into N variables to match a set of N qubits available to run a classification algorithm using a gate-based quantum circuit.…”

Navigating with chemometrics and machine learning in chemistry

“…Using binding affinity scores, 10 potential drug candidates were suggested by their model for treating infections. A state-of-the-art quantum computing ML-based framework was designed as an in silico tool for discovering novel drug candidates against COVID-19 (Mensa et al 2022 ). A novel MP-GNN model and featurization was reported to designing COVID-19 drugs (Li et al 2022 ).…”